

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

For the quarterly period ended March 29, 2025

Or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission file number: 0-27598

**IRIDEX CORPORATION**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

77-0210467  
(I.R.S. Employer  
Identification Number)

1212 Terra Bella Avenue  
Mountain View, California  
(Address of principal executive offices)

94043-1824  
(Zip Code)

Registrant's telephone number, including area code: (650) 940-4700

Securities registered pursuant to Section 12(b) of the Act:

Title of Class	Trading Symbol	Name of Exchange on Which Registered
Common Stock, par value \$0.01 per share	IRIX	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
Emerging growth company	<input type="checkbox"/>		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of shares of common stock, \$0.01 par value, issued and outstanding as of May 8, 2025 was 16,789,027.

---

## TABLE OF CONTENTS

<u>Items</u>	<u>Page</u>
<u>PART I. FINANCIAL INFORMATION</u>	5
Item 1. <u>Condensed Consolidated Financial Statements (Unaudited)</u>	5
<u>Unaudited Condensed Consolidated Balance Sheets as of March 29, 2025 and December 28, 2024</u>	5
<u>Unaudited Condensed Consolidated Statements of Operations for the three months ended March 29, 2025 and March 30, 2024</u>	6
<u>Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 29, 2025 and March 30, 2024</u>	7
<u>Unaudited Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 29, 2025 and March 30, 2024</u>	8
<u>Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 29, 2025 and March 30, 2024</u>	9
<u>Notes to Unaudited Condensed Consolidated Financial Statements</u>	10
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	22
Item 3. <u>Quantitative and Qualitative Disclosures about Market Risk</u>	25
Item 4. <u>Controls and Procedures</u>	25
<u>PART II. OTHER INFORMATION</u>	26
Item 1. <u>Legal Proceedings</u>	26
Item 1A. <u>Risk Factors</u>	26
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	26
Item 3. <u>Defaults Upon Senior Securities</u>	26
Item 4. <u>Mine Safety Disclosures</u>	26
Item 5. <u>Other Information</u>	26
Item 6. <u>Exhibits</u>	27
<u>Signatures</u>	29

## NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

- our future financial performance, including our expectations regarding our revenue, cost of revenue, gross profit or gross margin, operating expenses (including changes in sales and marketing, research and development and general and administrative expenses), and our ability to achieve and maintain future profitability;
- macroeconomic conditions, including impact of global pandemics or other public health emergencies or outbreaks, global and geopolitical uncertainty and tensions, tariffs, inflation concerns, unexpected changes in tax law or policy, and changing interest rates on our business and results of operations;
- customer acceptance and purchase of our existing products and new products;
- our ability to maintain and expand our customer base;
- competition from other products;
- the impact of foreign currency exchange rate and interest rate fluctuations on our results and sales;
- the pace of change and innovation in the markets in which we participate and the competitive nature of those markets;
- our business strategy and our plan to build our business;
- our ability to effectively manage our growth;
- the success of our strategic partnership with Topcon Corporation;
- our costs of manufacturing and reliance on third party manufacturers;
- our ability to forecast and meet product demand;
- our ability to discover defects in our products and systems;
- our international sales strategy;
- our operating results and cash flows;
- our beliefs and objectives for future operations;
- our relationships with third parties;
- our ability to maintain, protect, and enhance our intellectual property rights;
- our ability to maintain, protect, and enhance our information technology systems and data;
- our ability to maintain our facilities in good working order;
- our ability to recover the carrying value of goodwill;
- the impact of expensing stock options and other equity awards;
- our ability to successfully defend litigation brought against us;
- our ability to indemnify our directors and officers;
- our ability to repay indebtedness and have indebtedness forgiven;
- our ability to successfully expand in our existing markets and into new markets;
- our ability to comply with laws, policies, and regulations that currently apply or become applicable to our business both in the United States and internationally;
- our ability to attract and retain qualified employees and key personnel, and source suppliers;
- our ability to raise additional capital;
- our ability to issue additional shares of preferred stock;

- the future trading prices of our common stock; and
- our ability to pay dividends in the future.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

You should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations, and prospects. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the Securities and Exchange Commission (“SEC”) as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, and other factors described in and should be read in conjunction with the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. We cannot assure you that the results, events, and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements.

The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which such statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to conform such statements to actual results or revised expectations, except as required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make.

As used in this Quarterly Report on Form 10-Q, the terms “Company,” “IRIDEX,” “we,” “us” and “our” refer to IRIDEX Corporation, and its consolidated subsidiaries.

**PART I. FINANCIAL INFORMATION**

**Item 1. Condensed Consolidated Financial Statements (Unaudited)**

**IRIDEX Corporation**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(Unaudited, in thousands except share and per share data)

	March 29, 2025	December 28, 2024
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 7,244	\$ 2,387
Accounts receivable, net	6,680	5,951
Receivable from related party	2,706	2,443
Inventories	10,142	10,817
Prepaid expenses and other current assets	2,357	1,964
Total current assets	29,129	23,562
Property and equipment, net	75	115
Intangible assets, net	1,223	1,307
Goodwill	965	965
Operating lease right-of-use assets, net	1,546	1,792
Other long-term assets	1,298	1,394
Total assets	<u>\$ 34,236</u>	<u>\$ 29,135</u>
<b>LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 6,048	\$ 6,985
Payable to related party	660	609
Accrued compensation	2,015	1,672
Accrued expenses	969	477
Convertible note payable, current	-	1,734
Other current liabilities	2,045	1,812
Deferred revenue, current	2,090	2,176
Operating lease liabilities, current	1,120	1,094
Total current liabilities	14,947	16,559
Long-term liabilities:		
Deferred revenue	7,968	8,350
Operating lease liabilities	535	811
Convertible note payable	3,644	1,004
Other long-term liabilities	290	314
Total liabilities	27,384	27,038
Commitments and contingencies (Note 8)		
Series B convertible preferred stock, \$0.01 par value	6,000	-
Authorized: 2,000,000 shares;		
Issued and outstanding 600,000 shares as of March 29, 2025 and 0 as of December 28, 2024 (Liquidation preference of \$6 million as of March 29, 2025)		
Stockholders' equity:		
Common stock, \$0.01 par value:		
Authorized: 30,000,000 shares;		
Issued and outstanding 16,789,027 shares as of March 29, 2025 and 16,636,380 as of December 28, 2024	174	174
Additional paid-in capital	90,344	89,881
Accumulated other comprehensive income	29	51
Accumulated deficit	(89,695)	(88,009)
Total stockholders' equity	852	2,097
Total liabilities, convertible preferred stock, and stockholders' equity	<u>\$ 34,236</u>	<u>\$ 29,135</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**IRIDEX Corporation**  
**Condensed Consolidated Statements of Operations**  
(Unaudited, in thousands except per share data)

	Three Months Ended	
	March 29, 2025	March 30, 2024
Total revenues	\$ 11,896	\$ 11,761
Cost of revenues	6,841	7,303
Gross profit	5,055	4,458
Operating expenses:		
Research and development	876	1,536
Sales and marketing	2,453	3,747
General and administrative	1,931	2,468
Total operating expenses	5,260	7,751
Loss from operations	(205)	(3,293)
Other expense, net	(1,469)	(133)
Loss from operations before provision for income taxes	(1,674)	(3,426)
Provision for income taxes	12	38
Net loss	<u>\$ (1,686)</u>	<u>\$ (3,464)</u>
Net loss per share:		
Basic	<u>\$ (0.10)</u>	<u>\$ (0.21)</u>
Diluted	<u>\$ (0.10)</u>	<u>\$ (0.21)</u>
Weighted average shares used in computing net loss per common share:		
Basic	<u>16,727</u>	<u>16,253</u>
Diluted	<u>16,727</u>	<u>16,253</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**IRIDEX Corporation**  
**Condensed Consolidated Statements of Comprehensive Loss**  
**(Unaudited, in thousands)**

	Three Months Ended	
	March 29, 2025	March 30, 2024
Net loss	\$ (1,686)	\$ (3,464)
Change in foreign currency translation adjustments	(22)	36
Comprehensive loss	<u>\$ (1,708)</u>	<u>\$ (3,428)</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**IRIDEX Corporation**  
**Condensed Consolidated Statements of Stockholders' Equity**  
**(Unaudited, in thousands, except share data)**

For the three months ended March 29, 2025	Common Stock		Additional	Accumulated	Accumulated	Total
	Shares	Amount	Paid-in	Other	Deficit	Stockholders
			Capital	Comprehensive		Equity
				Income		
Balances, December 28, 2024	16,636,380	\$ 174	\$ 89,881	\$ 51	\$ (88,009)	\$ 2,097
Issuance of common shares in conjunction with extinguishment of convertible notes payable	152,647	—	250	—	—	250
Stock-based compensation expense	—	—	213	—	—	213
Other comprehensive loss	—	—	—	(22)	—	(22)
Net loss	—	—	—	—	(1,686)	(1,686)
Balances, March 29, 2025	<u>16,789,027</u>	<u>\$ 174</u>	<u>\$ 90,344</u>	<u>\$ 29</u>	<u>\$ (89,695)</u>	<u>\$ 852</u>

For the three months ended March 30, 2024	Common Stock		Additional	Accumulated	Accumulated	Total
	Shares	Amount	Paid-in	Other	Deficit	Stockholders
			Capital	Comprehensive		Equity
				Loss		
Balances, December 30, 2023	16,252,813	172	88,444	(52)	(79,042)	\$ 9,522
Stock-based compensation expense	—	—	394	—	—	394
Other comprehensive income	—	—	—	36	—	36
Net loss	—	—	—	—	(3,464)	(3,464)
Balances, March 30, 2024	<u>16,252,813</u>	<u>\$ 172</u>	<u>\$ 88,838</u>	<u>\$ (16)</u>	<u>\$ (82,506)</u>	<u>\$ 6,488</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**IRIDEX Corporation**  
**Condensed Consolidated Statements of Cash Flows**  
(Unaudited, in thousands)

	Three Months Ended	
	March 29, 2025	March 30, 2024
<b>Operating activities:</b>		
Net loss	\$ (1,686)	\$ (3,464)
<b>Adjustments to reconcile net loss to net cash used in operating activities:</b>		
Loss on extinguishment of convertible note payable	1,335	—
Depreciation and amortization	135	173
Amortization of operating lease right-of-use assets	246	230
Accretion of original issue discount	58	—
Amortization of debt issuance costs	78	—
Stock-based compensation	213	394
<b>Changes in operating assets and liabilities:</b>		
Accounts receivable	(729)	202
Receivable from related party	(263)	306
Inventories	675	(1,097)
Prepaid expenses and other current assets	(393)	(1,154)
Other long-term assets	96	72
Accounts payable	(1,291)	3,182
Payable to related party	51	82
Accrued compensation	343	637
Accrued expenses	492	(884)
Deferred revenue	(468)	(274)
Operating lease liabilities	(250)	(225)
Other liabilities	209	172
Net cash used in operating activities	(1,149)	(1,648)
<b>Investing activities:</b>		
Acquisition of property and equipment	(11)	(3)
Net cash used in investing activities	(11)	(3)
<b>Financing activities:</b>		
Proceeds from issuance of convertible note payable	4,000	—
Payments on note payable	(3,961)	—
Proceeds from issuance of Series B preferred stock	6,000	—
Net cash provided by financing activities	6,039	—
Effect of foreign exchange rate changes	(22)	36
Net increase (decrease) in cash and cash equivalents	4,857	(1,615)
Cash and cash equivalents, beginning of year	2,387	7,034
Cash and cash equivalents, end of year	<u>\$ 7,244</u>	<u>\$ 5,419</u>
<b>Supplemental disclosure of cash flow activities:</b>		
Cash paid during the period for income taxes	\$ 24	\$ —
<b>Supplemental disclosure of non-cash activities:</b>		
Debt issuance cost	\$ 360	\$ —
Issuance of common shares in conjunction with extinguishment of convertible notes payable	\$ 250	\$ —

The accompanying notes are an integral part of these condensed consolidated financial statements.

**IRIDEX Corporation**  
**Notes to Unaudited Condensed Consolidated Financial Statements**

**1. Basis of Presentation**

The accompanying unaudited condensed consolidated financial statements of IRIDEX Corporation (“IRIDEX”, the “Company”, “we”, “our”, or “us”) have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the financial statements have been included.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, together with management’s discussion and analysis of the Company’s financial condition and results of operations, contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2024, which was filed with the SEC on March 27, 2025. The results of operations for the three months ended March 29, 2025 are not necessarily indicative of the results for the fiscal year ending January 3, 2026 or any future interim period. The three months ended March 29, 2025 and March 30, 2024 each had 13 weeks. For purposes of reporting the financial results, the Company’s fiscal years end on the Saturday closest to the end of December. Periodically, the Company includes a 53rd week to a year in order to end that year on the Saturday closest to the end of December.

**2. Summary of Significant Accounting Policies**

The Company’s significant accounting policies are disclosed in our Annual Report on Form 10-K for the year ended December 28, 2024 which was filed with the SEC on March 27, 2025.

*Financial Statement Presentation*

The unaudited condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

*Use of Estimates*

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on our operating results.

*Segment Reporting*

The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.

*Revenue Recognition*

Our revenues arise from the sale of laser consoles, delivery devices, consumables, service, and support activities. We also derive revenue from royalties from third parties which are typically based on the licensees’ net sales of products that utilize our technology. Our revenue is recognized in accordance with Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers.” The Company recognizes revenue using the five-step model: (1) identifying the contract with the customer, (2) identifying the performance obligations in the contract, (3) determining expected transaction price, (4) allocating the transaction price to the distinct performance obligations in the contract, and (5) recognizing revenue when (or as) the performance obligations are satisfied.

The Company has the following revenue transaction types: (1) Product Sale Only, (2) Service Contracts, (3) System Repairs (outside of warranty), (4) Royalty Revenue and (5) Exclusive Distribution Rights.

1.Product Sale Only: The Company’s products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes. The Company’s products are currently sold for use by ophthalmologists specializing in the treatment of glaucoma and retinal diseases. Inside the United States and Germany the products are sold directly to the end users. In other countries outside of the United States and Germany, the Company utilizes independent, third-party

distributors to market and sell the Company's products. There is no continuing obligation after shipment is made to these distributors.

The Company recognizes revenue from product sales at a point in time subject to the allocation of transaction price to additional performance obligations, if any.

2. Service Contracts: The Company offers a standard two-year warranty on all system sales. The Company also offers a service contract which is sold to customers in incremental, one-year periods that begin subsequent to the expiration of the standard two-year warranty. The customer can opt to purchase the service contract at the time of the system sale or after the initial system sale.

The Company recognizes revenue from service contracts ratably over the service period. Revenue recognition for the sale of a service contract is largely dependent on the timing of the sale as follows:

a) Service Contract Sale in Conjunction with System Sale: If the customer opts to purchase a service contract at the time of the system sale, the Company allocates the transaction price of the distinct performance obligations in the contract by determining stand-alone selling price using historical pricing net of any variable consideration or discounts to specifically allocate to a particular performance obligation.

b) Service Contract Sale Subsequent to System Sale: If the customer opts to purchase a service contract after the initial system sale, the Company determines the amount of time that has elapsed since the initial system sale. If the service contract is purchased within 60 days of the initial sale, the Company considers this sale to be an additional element of the original sale and allocates the transaction price of the distinct performance obligations in the contract by determining stand-alone selling price using historical pricing net of any variable consideration or discounts to specifically allocate to a particular performance obligation. If the service contract is purchased subsequent to 60 days after the initial sale, the sale of the service contract is deemed a separate contract and is deferred at the selling price and recognized ratably over the extended warranty period as the performance obligation is satisfied.

3. System Repairs (outside of warranty): Customers will occasionally request repairs from the Company subsequent to the expiration of the standard warranty and outside of a service contract.

The Company recognizes revenue from system repairs (outside of warranty) at a point in time. When the customer requests repairs from the Company subsequent to the expiration of the standard warranty and outside of a service contract, these repair contracts are considered separate from the initial sale. As such, revenue is recognized as the repair services are rendered and the performance obligation is satisfied.

4. Royalty Revenue: The Company has royalty agreements with four customers related to the sale of the Company's intellectual property. Under the terms of these agreements, two customers are to remit a percentage of sales to the Company as the sales occur and one customer made an upfront prepayment for royalties.

The arrangements with three customers are for sales-based licenses of intellectual property, for which the guidance in paragraph ASC 606-10-55-65 applies. Therefore, the Company recognizes revenue at a point in time, only as the subsequent sale occurs. However, the Company notes that such sales being reported by the licensee with a quarter in arrears, such revenue is recognized at the time it is reported and paid by the licensee given that any estimated variable consideration would have to be fully constrained due to the unpredictability of such estimate and the unavoidable risk that it may lead to significant revenue reversals. For the arrangement with one customer, the Company had concluded that there is one combined performance obligation to be satisfied. Therefore, the Company recognizes revenue related to this arrangement over time.

5. **Exclusive Distribution Rights:** On March 2, 2021, the Company and Topcon Corporation (“Topcon”) entered into a distribution agreement (“Distribution Agreement”), pursuant to which the Company granted Topcon the exclusive right to distribute the Company’s retina and glaucoma products in certain geographies outside the United States. The exclusivity arrangement with Topcon obligates the Company to provide training, customer support, and exclusive territorial rights to Topcon for certain international regions, for a period of 10 years, commencing upon regulatory approval to transfer existing (non-exclusive) distribution rights from the current distributors in those regions to Topcon. The Company has the right to terminate the exclusive distribution rights granted to Topcon for any of the regions at any point in time during the 10-year exclusivity term for a termination fee that is based on a multiple of 1.2 times the revenue generated by the Company in 2019 for the respective region. Management has determined that the exclusivity rights, training, and customer support represents a single combined performance obligation for each region, to be recognized as exclusivity fee revenue on a straight-line basis over the 10-year period for each region, commencing on the date that regulatory approval is obtained for each region, based on the standalone selling price for such combined performance obligation for each region. The estimated fair value of the exclusive distribution rights for all regions combined totaled approximately \$14.8 million. Of this amount, management has fully-constrained and returned to Topcon the arrangement fee allocated to Belarus (approximately \$0.2 million) because obtaining the necessary regulatory approvals and termination of existing distributor relationship was not feasible. For each of the three months ended March 29, 2025 and March 30, 2024, \$0.4 million in revenue related to the exclusive distribution rights were recorded.

#### *Costs of Obtaining Revenue Contracts*

The Company recognized assets from certain costs incurred to obtain revenue contracts. These costs relate to sales commissions arising from the sale of our products. The costs are considered incremental and recoverable of obtaining revenue contracts with customers. These deferred costs are amortized on a straight-line basis over the estimated period of benefit, which typically ranges from 2 to 3 years. As of March 29, 2025, the Company recognized deferred costs incurred to obtain revenue contracts with customers, net of accumulated amortization, of \$4 thousand, and included these amounts in Prepaid expenses and other current assets and Other long-term assets in the Company’s condensed consolidated balance sheets. Amortization expense was \$19 thousand for each of the three months ended March 29, 2025 and March 30, 2024. There were no impairment expenses for both the three months ended March 29, 2025 and March 30, 2024.

Sales commissions that do not represent incremental and recoverable costs of obtaining a contract are expensed as incurred. As a practical expedient, the Company will not recognize such sales commission as a contract asset but rather recognize as an expense when incurred if the amortization period of the asset that the Company would have otherwise recognized is one year or less.

#### *Contract Fulfillment Costs*

The Company recognized an asset from the costs incurred to fulfill a contract. These costs relate directly and must be incurred to satisfy performance obligations on certain specific contract with a customer. These costs are expected to be recovered over time and are amortized on a systematic basis that is consistent with the recognition of revenue to which it relates. As of March 29, 2025, the Company recognized deferred costs incurred to fulfill a contract with a customer, net of accumulated amortization, of \$0.6 million, and included these amounts in Prepaid expenses and other current assets and Other long-term assets in the Company’s condensed consolidated balance sheets. Amortization expense was \$21 thousand for each of the three months ended March 29, 2025 and March 30, 2024. There were no impairment expenses for each of three months ended March 29, 2025 and March 30, 2024.

#### *Leases*

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, net and Operating lease liabilities in our condensed consolidated balance sheets. As of March 29, 2025 and December 28, 2024, the Company was not a party to any finance lease arrangements.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on information available at the commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Under the available practical expedient, we account for the lease and non-lease components as a single lease component.

#### *Concentration of Credit Risk and Other Risks and Uncertainties*

Our cash and cash equivalents are deposited in demand and money market accounts. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand.

We market our products to distributors and end-users throughout the world. Sales to international distributors are generally made on open credit terms and letters of credit. Management performs ongoing credit evaluations of our customers and maintains a

provision for potential credit losses. Historically, we have not experienced any significant losses related to individual customers or a group of customers in any particular geographic area. For the three months ended March 29, 2025 and March 30, 2024, one customer, Topcon, accounted for more than 10% of total revenues, representing 30% and 32%, respectively. For the three months ended March 29, 2025 and March 30, 2024, one customer, Topcon, accounted for over 10% of our accounts receivable, representing 29% and 28%, respectively.

#### *Taxes Collected from Customers and Remitted to Governmental Authorities*

Taxes collected from customers and remitted to governmental authorities are recognized on a net basis in the accompanying condensed consolidated statements of operations.

#### *Shipping and Handling Costs*

Our shipping and handling costs billed to customers are included in revenues and the associated expense is recorded in cost of revenues for all periods presented.

#### *Deferred Revenue*

Deferred revenue represents contract liabilities and exclusivity fees. Revenue related to service contracts is deferred and recognized on a straight-line basis over the period of the applicable service contract. Costs associated with these service arrangements are recognized as incurred. Revenue related to exclusivity fees is deferred and recognized over the related exclusivity period.

A reconciliation of the changes in the Company's deferred revenue balance for the three months ended March 29, 2025 and March 30, 2024, is as follows:

	Three Months Ended	
	March 29, 2025	March 30, 2024
Balance, beginning of period	\$ 10,526	\$ 12,429
Additions to deferral	329	457
Revenue recognized	(797)	(731)
Balance, end of the period	10,058	12,155
Non-current portion of deferred revenue	7,968	9,708
Current portion of deferred revenue	<u>\$ 2,090</u>	<u>\$ 2,447</u>

During the three months ended March 29, 2025 and March 30, 2024, approximately \$0.6 million and \$0.7 million were recognized pertaining to amounts deferred as of December 28, 2024 and December 30, 2023, respectively. As of March 29, 2025, approximately \$7.9 million of the non-current portion of deferred revenue and \$1.5 million of the current portion of deferred revenue pertain to exclusivity distribution rights deferred revenue.

#### *Warranty*

The Company currently provides a two-year full warranty on its products. The associated costs of these warranties are accrued for upon shipment of the products. The Company's warranty policy is applicable to products which are considered defective in their performance or fail to meet the product specifications. Warranty costs are reflected in the condensed consolidated statements of operations as cost of revenues.

As warranty reserves do not meet the criteria to have separate captions on the face of the condensed balance sheet, we removed these captions and included those amounts in other current and long-term liabilities.

#### *Implementation Costs Incurred in a Cloud Computing Service Arrangement*

In 2023, the Company completed implementing its new enterprise resource planning ("ERP") system. The new ERP system operates in a cloud-based environment. The Company concluded that this cloud computing arrangement does not include a license, and therefore, will account for this arrangement as one that is a service contract. The Company capitalized \$1.1 million in implementation costs and began utilizing the ERP system near the end of the third quarter of 2023 and is recognizing amortization of the capitalized implementation costs over five years on a straight-line basis. Amortization expense was approximately \$57 thousand for each of the three months ended March 29, 2025 and March 30, 2024.

#### *Recent Accounting Standards Not Yet Adopted*

In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our consolidated financial statement disclosures.

In November 2024, the FASB issued ASU 2024-03 "Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses", which requires disclosure of

disaggregated information about certain income statement expense line items on an annual and interim basis. This update will be effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. As this accounting standard only impacts disclosures, it will not have a material impact on the Company's consolidated financial statements.

### 3. Accounts Receivable and Provision for Credit Losses

The Company has trade receivables with various individual customers such as private businesses, hospitals, universities, government and non-profit entities, and distributors. The Company has determined that geography is the similar risk characteristic to pool our trade receivables balances, and accordingly, groups such balances into either the domestic pool or the international pool. The domestic pool is primarily comprised of individual customers, and the international pool is primarily comprised of distributors.

The provision for credit losses represents an estimate of the lifetime expected credit losses inherent in trade receivables as of the consolidated balance sheet date. We assess the adequacy of the provision for credit losses on a quarterly basis based on historical information and current economic conditions and forecasts. Subsequent changes in the provision for credit losses are recorded in current earnings and reversal of previous losses are permitted under the current guidance.

While we believe we have exercised prudent judgment and applied reasonable assumptions, there can be no assurance that in the future, changes in economic conditions or other factors would not cause changes in the financial health of our customers. If the financial health of our customers deteriorates, the timing and level of payments received could be impacted and therefore, could result in a change to our estimated losses.

The following table presents the activity in the provision for credit losses for accounts receivable by pool type for the three months ended March 29, 2025 (in thousands):

	Domestic	International	Total
Balance, beginning of period	\$ (145)	\$ (114)	\$ (259)
Change to provision	67	80	147
Balance, end of period	<u>\$ (78)</u>	<u>\$ (34)</u>	<u>\$ (112)</u>

### 4. Related Party - Topcon

As of March 29, 2025, Topcon holds a 10% voting interest in the Company, which qualifies it to be a principal owner and considered a related party, even though it currently does not have significant influence over the Company's operations.

Topcon resells certain of our products as our exclusive distributor in certain international regions. At the same time, the Company also purchases certain raw materials from Topcon. During the three months ended March 29, 2025, the Company's revenues related to Topcon amounted to approximately \$3.6 million, including \$0.4 million in recognized exclusive distribution rights revenue. During the three months ended March 30, 2024, the Company's revenues related to Topcon amounted to approximately \$3.8 million, including \$0.4 million in recognized exclusive distribution rights revenue. The Company's purchases from Topcon during the three months ended March 29, 2025 amounted to approximately \$0.3 million. As of March 29, 2025, the amounts receivable from and payable to Topcon were \$2.7 million and \$0.7 million, respectively. As of December 28, 2024, the amounts receivable from and payable to Topcon were \$2.4 million and \$0.6 million, respectively.

### 5. Inventories

The components of the Company's inventories as of March 29, 2025 and December 28, 2024 are as follows:

	March 29, 2025	December 28, 2024
Raw materials	\$ 3,848	\$ 4,236
Work in process	-	-
Finished goods	6,294	6,581
Total inventories	<u>\$ 10,142</u>	<u>\$ 10,817</u>

### 6. Goodwill and Intangible Assets

#### Goodwill

The carrying value of goodwill was \$1.0 million as of both March 29, 2025 and December 28, 2024.

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company performs an annual impairment test by comparing

the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax-deductible goodwill carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to assess impairment, its common stock price is an important component of the fair value calculation. If the Company's stock price continues to experience significant price and volume fluctuations, this will impact the fair value of the reporting unit and can lead to potential impairment in future periods. The Company performed its annual impairment test during the second quarter of fiscal year 2024 and determined that its goodwill was not impaired.

#### Intangible Assets

The following table summarizes the components of gross and net of intangible assets carrying amounts (in thousands):

	March 29, 2025				December 28, 2024			
	Gross Carrying Value	Accumulated Amortization	Net Carrying Value	Useful Lives Remaining	Gross Carrying Value	Accumulated Amortization	Net Carrying Value	
Customer relations	\$ 340	\$ 298	\$ 42	2.92 Years	\$ 340	\$ 290	\$ 50	
Developed technology	1,899	882	1,017	3.92 Years	1,899	814	1,085	
Trade names	300	136	164	4.92 Years	300	128	172	
	<u>\$ 2,539</u>	<u>\$ 1,316</u>	<u>\$ 1,223</u>		<u>\$ 2,539</u>	<u>\$ 1,232</u>	<u>\$ 1,307</u>	

Amortization expense was \$84 thousand for both the three months ended March 29, 2025 and March 30, 2024.

The amortization of developed technology was charged to research and development expense and the amortization of customer relations and trade names was charged to sales and marketing expense. Estimated future amortization expense for purchased intangible assets is as follows (in thousands):

Fiscal Year:	
Remainder of 2025 (nine months)	\$ 239
2026	319
2027	319
2028	200
2029	140
Thereafter	6
Total	<u>\$ 1,223</u>

#### 7. Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

- Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.
- Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.

•Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.

The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of March 29, 2025 and December 28, 2024, approximate fair value because of the short maturity of these instruments.

As of March 29, 2025 and December 28, 2024, financial assets measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above were as follows (in thousands):

(in thousands)	As of March 29, 2025				As of December 28, 2024			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
<b>Assets:</b>								
Money market funds	\$ 6,237	\$ —	\$ —	\$ 6,237	\$ 397	\$ —	\$ —	\$ 397

The Company’s Level 1 financial assets are money market funds whose fair values are based on quoted market prices. The Company does not have any Level 2 and Level 3 financial assets or liabilities.

## 8. Leases and Commitments and Contingencies

### Operating Leases

Our operating leases consist of facility and office equipment leases. Operating lease expenses for the three months ended March 29, 2025 and March 30, 2024 were \$0.3 million. The weighted average discount rate used in calculating the present value of lease payments was 4.8%. As of March 29, 2025, the weighted average remaining lease term for our operating leases was 1.5 years.

The following represents maturities of operating lease liabilities as of March 29, 2025 (in thousands):

Fiscal Year	Operating Lease Payments
Remainder of 2025 (nine months)	\$ 923
2026	781
2027	20
2028	20
2029	9
Total lease payments	1,753
Less: Imputed interest	(98)
Total lease liabilities	1,655
Non-current portion of lease liabilities	(535)
Current portion of lease liabilities	\$ 1,120

### Purchase Commitments

Our purchase commitments consist primarily of non-cancellable purchase commitments with vendors to manufacture certain components and ophthalmic instrumentation. As of March 29, 2025, our future minimum payments through fiscal year 2027 for our purchase commitments were approximately \$13.1 million, with \$9.8 million committed for the next 12 months.

### Indemnities

We enter into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties (generally our business partners or customers) in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to our products. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments that we could be required to make under these agreements is not determinable. We have never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the estimated fair value of these agreements is minimal.

We have entered into indemnification agreements with our directors and officers that may require us to indemnify our directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising

from willful misconduct of a culpable nature. These agreements also require us to advance their expenses incurred as a result of any proceeding against them as to which they could be indemnified and to make good faith determination whether or not it is practicable for us to obtain directors and officers insurance. We currently have directors and officers liability insurance.

#### Legal Proceedings

From time to time, we may be involved in legal proceedings arising in the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business condensed consolidated operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

#### 9. Convertible Preferred Shares and Convertible Debt

On March 18, 2025, the Company filed a Certificate of Designation authorizing the Company to issue up to 1,000,000 shares of authorized undesignated preferred stock as shares of Series B Preferred stock, par value \$0.01 per share (the “Series B Preferred Stock”).

On March 19, 2025, the Company entered into a securities purchase agreement (the “Novel Securities Agreement”) and a Note Purchase Agreement (the “Novel Note Purchase Agreement”) with Novel Inspirational International Co., Ltd. (“Novel”). Pursuant to the Novel Securities Agreement and the Novel Note Purchase Agreement, the Company issued 600,000 shares of its Series B Preferred Stock at \$10.00 per share, initially convertible into 3,000,000 shares of the Company’s common stock, par value \$0.01 per share and an initial convertible promissory note in an aggregate principal amount of \$4,000,000 (the “Initial Novel Note” and together with the Novel Growth Notes (as defined below), the “Novel Notes”). The Initial Novel Note is convertible into 400,000 shares of the Company’s Series B Preferred Stock.

Concurrently with the purchase of the shares of Series B Preferred Stock and the Initial Novel Note, the Company also entered into an Investor Rights Agreement (the “Rights Agreement”) with Novel, pursuant to which the Company has agreed to, among other matters, grant Novel certain rights, including: (i) registration rights and indemnification obligations related thereto; (ii) subject to certain restrictions (including satisfying certain beneficial ownership thresholds), the right to appoint and maintain two individuals to the Company’s board of directors, which was effective as of March 19, 2025; and (iii) the right to approve certain corporate actions of the Company.

The Initial Novel Note has a 36-month term and will bear interest at 12% per annum. Interest on the Initial Novel Note will be payable quarterly on the first business day of each calendar quarter, beginning on July 1, 2025, in a number of shares of the common stock equal to (i) the accrued and unpaid interest due on the applicable interest payment date divided by (ii) the greater of (a) the average closing price of the common stock for each trading day after March 19, 2025 in the calendar quarter immediately preceding such interest payment date and (b) a price floor of \$0.21. The Initial Novel Note is convertible at Novel’s option into shares of the Series B Preferred Stock at an initial conversion price of \$10.00, subject to adjustments set forth in the Initial Novel Note. In addition, the Company incurred \$0.4 million in debt issuance costs. For the three months ended March 29, 2025, \$4 thousand of debt issuance costs were recorded on a straight-line basis over the term of the loan. The accretion of debt issuance costs under that under method is deemed materially consistent with the effective interest rate method.

The following represents the payments of notes payable as of March 29, 2025 (in thousands):

Fiscal Year	Payments
Remainder of 2025 (nine months)	\$ -
2026	-
2027	-
2028	4,000,000
<b>Total payments</b>	<b>\$ 4,000,000</b>

In addition to the Initial Novel Note, Novel has the right to purchase additional convertible promissory notes (the “Growth Notes”) in an aggregate principal amount of \$10,000,000. The Growth Notes are issuable in three installments, with one third of the aggregate principal amount issuable upon each yearly anniversary of the March 19, 2025. Notwithstanding any provision in the Transaction Documents (as defined in the Initial Novel Note) to the contrary, in no circumstance shall the Company be required to deliver to Novel any shares of Series B Preferred Stock or common stock pursuant to the terms of the Transaction Documents to the extent that (i) the aggregate of all such shares issued by the Company would exceed 19.99% of either (a) the total number of shares of common stock outstanding as of March 19, 2025 or (b) the total voting power of the Company’s securities outstanding as of March 19, 2025 that are entitled to vote on a matter being voted on by holders of the common stock, or (ii) such delivery would cause the holder to become, directly or indirectly, a “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) of more than 19.99% of either (a) the total number of shares of common stock outstanding as of such date or (b) the total

voting power of the Company's securities outstanding as of such date that are entitled to vote on a matter being voted on by holders of the common stock, in each case, unless shareholder approval has been obtained.

On March 18, 2025, the Company also entered into that certain repayment notice (the "Repayment Notice") with Lind Global Asset Management IX LLC ("Lind"). Pursuant to the Repayment Notice and upon the subsequent delivery of a cash payment to Lind, the Company thereafter fully discharged its outstanding obligations (other than certain indemnification obligations that survived pursuant to the terms of the Repayment Notice) under that certain Securities Purchase Agreement, dated August 4, 2024, by and between the Company and Lind, and terminated the Senior Convertible Promissory Note, dated August 7, 2024, issued by the Company to Lind thereunder. As a result of the early repayment of the Lind's notes on March 19, 2025, the Company recognized a loss of \$1.3 million on the extinguishment of the convertible note payable.

## 10. Stock-Based Compensation

The Company accounts for stock-based compensation granted to employees and directors, including stock option awards, restricted stock and restricted stock units ("RSUs") in accordance with FASB ASC Topic 718, "Compensation – Stock Compensation" ("ASC 718"). Accordingly, stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee's service period. The Company recognizes compensation expense on a ratable basis over the requisite service period of the award.

The Company values options using the Black-Scholes option pricing model. Time-based RSUs are valued at the grant date fair value of the underlying common shares. Performance-based RSUs without market conditions are valued at grant date fair value of the underlying common shares. Performance-based RSUs granted with market conditions and performance-based stock options with market conditions are valued using the Monte Carlo simulation model. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of stock-based awards, including the option's expected term and the price volatility of the underlying stock. The Monte Carlo simulation model incorporates assumptions for the holding period, risk-free interest rate, stock price volatility and dividend yield.

### 2008 Equity Incentive Plan, as amended.

The terms of awards granted during the three months ended March 29, 2025 were consistent with those described in the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 28, 2024.

The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three months ended March 29, 2025 and March 30, 2024 (in thousands):

	Three Months Ended	
	March 29, 2025	March 30, 2024
Cost of revenues	\$ 18	\$ 60
Research and development	29	52
Sales and marketing	66	111
General and administrative	100	171
Total stock-based compensation expense	<u>\$ 213</u>	<u>\$ 394</u>

Stock-based compensation expense capitalized to inventory was immaterial for the three months ended March 29, 2025 and March 30, 2024.

As of March 29, 2025, there was \$1.2 million of total unrecognized compensation cost, net of expected forfeitures, related to non-vested stock-based compensation arrangements. The cost is expected to be recognized over a weighted average period of 1.5 years.

### Summary of Stock Options

The following table summarizes stock options information during the three months ended March 29, 2025:

	Number of Shares	Weighted Average Exercise Price Per Share	Aggregate Intrinsic Value (thousands)
Outstanding as of December 28, 2024	1,692,707	\$ 2.89	
Granted	63,000	\$ 0.92	
Canceled or forfeited	(144,501)	\$ 3.47	
Outstanding as of March 29, 2025	<u>1,611,206</u>	\$ 2.76	\$ 5,782

The weighted average grant date fair value of the options granted was \$0.70 and \$1.75 per share for the three months ended March 29, 2025 and March 30, 2024, respectively.

The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock-based awards (options) with the following weighted-average assumptions:

	Three Months Ended	
	March 29, 2025	March 30, 2024
Average risk free interest rate	4.02%	4.20%
Expected life (in years)	4.50	4.4
Dividend yield	—	—
Average volatility	106%	79%

Option-pricing models require the input of various subjective assumptions, including the option's expected life and the price volatility of the underlying stock. The expected stock price volatility is based on an analysis of the Company's stock price history over a period commensurate with the expected term of the options, trading volume of the Company's stock, look-back volatilities and Company-specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No dividend yield is included as the Company has not issued any dividends and does not anticipate issuing any dividends in the future.

Information regarding stock options outstanding, vested, expected to vest, and exercisable as of March 29, 2025 is summarized below:

	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value (thousands)
Options outstanding	1,611,206	\$ 2.76	3.59	\$ 5,782
Options vested and expected to vest	1,562,323	\$ 2.79	3.53	\$ 4,707
Options exercisable	1,014,683	\$ 3.16	2.73	\$ -

The aggregate intrinsic value in the table above represents the pre-tax intrinsic value, based on the Company's closing price as of March 29, 2025, that would have been received by option holders had all option holders exercised their stock options as of that date. This amount changes based on the fair market value of the Company's common stock. There were no options exercised during each of the three months ended March 29, 2025 and March 30, 2024.

#### Summary of RSUs

Information regarding RSUs activity for the three months ended March 29, 2025 is as summarized below:

	Number of Shares
Outstanding as of December 28, 2024	615,707
Restricted stock units granted	5,000
Restricted stock units forfeited	(5,000)
Outstanding as of March 29, 2025	<u>615,707</u>

## 11. Income Taxes

### Provision for Income Tax

The Company calculates its interim tax provision in accordance with the provisions of ASC Topic 740-270, *Income Taxes; Interim Reporting*. For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company recorded

a provision for income tax of \$12 thousand and \$38 thousand for the three months ended March 29, 2025 and March 30, 2024, respectively.

#### *Deferred Income Taxes*

The Company accounts for income taxes in accordance with ASC Topic 740, *Income Taxes* (“ASC 740”), which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. ASC 740 also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. As of the first quarter of fiscal year 2025, based on the Company’s recent history of losses and its forecasted losses, management believes on the more-likely-than-not basis that a full valuation allowance is required. Accordingly, the Company continues to provide a full valuation allowance on its federal and states deferred tax assets.

#### *Uncertain Tax Positions*

The Company accounts for its uncertain tax positions in accordance with ASC 740. As of December 28, 2024, the Company had \$1.4 million of unrecognized tax benefits, none of the unrecognized tax benefits would result in a change in the Company’s effective tax rate if recognized in future years.

The Company is not aware of any other uncertain tax positions that could result in significant additional payments, accruals, or other material deviation in this estimate during the fiscal year.

The Company is subject to United States federal income tax as well as to income taxes in state jurisdictions. The Company’s federal and state income tax returns are open to examination by tax authorities for three years and three to five years, respectively.

## **12. Computation of Basic and Diluted Net Loss Per Share**

Basic and diluted net loss per share is based upon the weighted average number of common shares outstanding during the period. Common stock equivalents consist of incremental common shares issuable upon the exercise of stock options, and the release (vesting) of RSUs and awards and are calculated under the treasury stock method. Common stock equivalent shares from unexercised stock options, and unvested RSUs and awards are excluded from the computation for periods in which we incur a net loss or if the exercise price of such options is greater than the average market price of our common stock for the period as their effect would be anti-dilutive. Common stock equivalents consist of incremental common shares issuable upon conversion of convertible debt and preferred shares are calculated under the if-converted method. Common stock equivalent shares from convertible debt and preferred shares are excluded from the computation for periods in which we incur a net loss or if their effect would be anti-dilutive.

For the three months ended March 29, 2025 and March 30, 2024, potential shares from stock options and RSUs totaling 2,269,639 and 3,201,628 shares, respectively, were excluded from the computation of diluted weighted average shares outstanding. For the three months ended March 29, 2025 and March 30, 2024, potential shares from the conversion of convertible debt and preferred shares totaling 5,000,000 and 0 were excluded from the computation of diluted weighted average shares outstanding, respectively. However, notwithstanding any provision in the transaction documents with Novel to the contrary, in no circumstance shall the Company be required to deliver to Novel any shares of Series B Preferred Stock or common stock pursuant to the terms of the Transaction Documents to the extent that (i) the aggregate of all such shares issued by the Company would exceed 19.99% of either (a) the total number of shares of common stock outstanding as of March 19, 2025 or (b) the total voting power of the Company’s securities outstanding as of March 19, 2025 that are entitled to vote on a matter being voted on by holders of the common stock, or (ii) such delivery would cause the holder to become, directly or indirectly, a “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) of more than 19.99% of either (a) the total number of shares of common stock outstanding as of such date or (b) the total voting power of the Company’s securities outstanding as of such date that are entitled to vote on a matter being voted on by holders of the common stock, in each case, unless shareholder approval has been obtained.

A reconciliation of the numerator and denominator of basic and diluted net loss per common share is provided as follows (in thousands except per share data):

	Three Months Ended	
	March 29, 2025	March 30, 2024
<b>Numerator:</b>		
Net loss	\$ (1,686)	\$ (3,464)
<b>Denominator:</b>		
Weighted average shares of common stock (basic)	16,727	16,253
Weighted average shares of common stock (diluted)	16,727	16,253
<b>Per share data:</b>		
Basic net loss per share	\$ (0.10)	\$ (0.21)
Diluted net loss per share	\$ (0.10)	\$ (0.21)

### 13. Business Segments

The Company operates in one segment: ophthalmology. The Company develops, manufactures and markets medical devices. Our revenues arise from the sale of consoles, delivery devices, consumables, service, and support activities.

Revenue information shown by product group is as follows (in thousands):

	Three Months Ended	
	March 29, 2025	March 30, 2024
Cyclo G6	\$ 3,181	\$ 2,953
Retina	6,645	6,774
Other(1)	2,070	2,034
Total revenues	\$ 11,896	\$ 11,761

(1) Includes service contract revenues of \$334 thousand and \$328 thousand recognized during the three months ended March 29, 2025 and March 30, 2024, respectively. Includes \$364 thousand recognized revenue related to the exclusive distribution rights during both of the three months ended March 29, 2025 and March 30, 2024. Other also includes revenues from paid service, royalty, freight and legacy G probes.

Revenue information shown by geographic region, based on the sales destination, is as follows (in thousands):

	Three Months Ended	
	March 29, 2025	March 30, 2024
United States	\$ 5,283	\$ 5,321
Europe, Middle East and Africa	2,861	3,698
Asia/Pacific Rim	3,360	2,444
Americas, excluding the U.S.	392	298
	\$ 11,896	\$ 11,761

Revenues are attributed to countries based on the location of end customers.

Other than the United States, the Netherlands accounted for at least 10% of the Company's revenues during the three months ended March 29, 2025, representing 13.1%. Other than the United States, the Netherlands accounted for at least 10% of the Company's revenues during the three months ended March 30, 2024, representing 21%. The United States accounted for 44.4% and 45.2% of revenues for the three months ended March 29, 2025 and March 30, 2024, respectively.

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions, that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management and should be read in conjunction with the section of this Quarterly Report on Form 10-Q entitled "Risk Factors." Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section entitled "Risk Factors."

### Overview

IRIDEX is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases.

Our propriety MicroPulse<sup>®</sup> Technology and Endpoint Management<sup>™</sup> Technology are used for the treatment of glaucoma and retina disorders. Both technologies are offered as optional treatment modes in select laser consoles in addition to the standard continuous-wave ("CW") treatment mode. They allow low-energy, subvisible, tissue-sparing laser therapy by different means: MicroPulse technology uses short, microsecond-long laser pulses that allow tissue to cool between pulses giving physicians finer control of thermal elevation to minimize tissue damage. Endpoint Management technology uses a delivery algorithm to titrate the laser energy. CW laser photocoagulation can stabilize vision over the long term but can also result in varying degrees of vision loss. Both MicroPulse and Endpoint Management technologies have demonstrated clinical efficacy with a safer profile compared to standard high-energy CW laser for the treatment of both retinal diseases and glaucoma.

Our products consist of laser consoles, delivery devices and consumable probes.

*Our laser consoles consist of the following product lines:*

- **Glaucoma** – Our primary glaucoma console line is the Cyclo G6<sup>®</sup> laser system with MicroPulse technology. In addition, our medical retina consoles have features supporting glaucoma laser treatments.
- **Medical Retina** – Our medical-retina product line includes our portable IQ 532<sup>®</sup> and IQ 577<sup>®</sup> laser systems with MicroPulse technology; and the Pattern Scanning Laser ("PASCAL") System, an integrated workstation with Endpoint Management technology and MicroPulse technology. These systems are ideal for multispecialty practices because these lasers also can be used to treat glaucoma, i.e., single-spot laser trabeculoplasty using MicroPulse technology, iridotomy, and iridectomy using the IQ lasers; and pattern scanning laser trabeculoplasty ("PSLT") using the PASCAL laser system.
- **Surgical Retina** – Our surgical-retina product line includes our OcuLight<sup>®</sup> TX and OcuLight<sup>®</sup> SLx (with MicroPulse technology) laser photocoagulation systems. These systems are often used in vitrectomy procedures, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments.

Our business generates recurring revenues through sales of consumable products, predominantly single-use laser probe devices and other instrumentation, as well as repair, service and extended service contracts for our laser systems.

*Our laser probes consist of the following product lines:*

- **Glaucoma** – Probes used in our glaucoma product line include our patented single-use delivery devices - MicroPulse P3<sup>®</sup>, G-Probe<sup>®</sup>, and G-Probe Illuminate<sup>®</sup>.
- **Surgical Retina** – Probes used in our surgical-retina product line include our family of single-use EndoProbe<sup>®</sup> handpieces.

Ophthalmologists typically use our laser systems in hospital operating rooms and ambulatory surgical centers, as well as their offices and clinics. In operating rooms and ambulatory surgical centers, ophthalmologists use our laser systems with either an indirect laser ophthalmoscope or a single-use consumable probe, including MicroPulse P3<sup>®</sup>, G-Probe<sup>®</sup> and G-Probe Illuminate<sup>®</sup> delivery devices, and EndoProbe handpieces. In the offices and clinics, ophthalmologists use our laser systems with either an indirect laser ophthalmoscope or a slit-lamp adapter.

Our products are sold in the United States and Germany predominantly through a direct sales force and internationally (aside from Germany, Italy, UK (Glaucoma), India, and other smaller markets) primarily through Topcon Corporation ("Topcon") and other independent distributors.

Sales to international distributors are made on open credit terms or letters of credit and are currently denominated in U.S. dollars and accordingly, are not subject to risks associated with currency fluctuations. However, increases in the value of the U.S. dollar against any local currencies could cause our products to become relatively more expensive to customers in a particular country or region, leading to reduced revenue or profitability in that country or region. Sales to direct end users transacted through our German office are denominated in Euros and are subject to risks associated with currency fluctuations.

Cost of revenues consists primarily of our direct manufacturing costs which include the cost of components and sub-systems, assembling, packaging, shipping and testing components at our facility, direct labor and associated overhead, warranty, royalty and amortization of intangible assets and depot service costs. For certain of our products, we are responsible for the cost of the fully assembled product that is manufactured by a third-party.

Research and development expenses consist primarily of personnel costs, materials to support new product development and research support provided to clinicians at medical institutions developing new applications which utilize our products and regulatory expenses. Research and development costs have been expensed as incurred.

Sales and marketing expenses consist primarily of costs of personnel, sales commissions, travel expenses, advertising and promotional expenses.

General and administrative expenses consist primarily of costs of personnel, legal, accounting and other public company costs, insurance and other expenses not allocated to other departments.

#### Impact of Macroeconomic Conditions to our Business

Current macroeconomic conditions exhibit challenges that can affect capital equipment purchasing demand and timing, including recessionary fears, inflation concerns, tariffs and retaliatory responses, trade wars, heightened interest rates as a result of government actions to combat inflation, and uncertainty in the global banking and financial services market, as well as other geopolitical developments, have impacted and may continue to impact business spending and the economy as a whole. As a result, we have seen customers extend purchase decision cycles. We have also experienced some demand softness due to pricing effects from the strength of the U.S. Dollar that have impacted and may continue to impact our operations.

The macroeconomic conditions on our business and operations remain uncertain, and it is not possible for us to predict the duration and extent to which they will affect our business, future results of operations, and financial condition.

For more information on risks associated with the current macroeconomic conditions, see the sections titled "Risk Factors" in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 28, 2024.

#### Results of Operations

The following table sets forth certain operating data as a percentage of revenues:

	Three Months Ended	
	March 29, 2025	March 30, 2024
Revenues	100.0%	100.0%
Cost of revenues	57.5%	62.1%
Gross margin	42.5%	37.9%
Operating expenses:		
Research and development	7.4%	13.1%
Sales and marketing	20.6%	31.9%
General and administrative	16.2%	21.0%
Total operating expenses	44.2%	66.0%
Loss from operations	(1.7%)	(28.1%)
Other income, net	(12.3%)	(1.1%)
Loss from operations before provision for income taxes	(14.0%)	(29.2%)
Provision for income taxes	0.1%	0.3%
Net loss	(14.1%)	(29.5%)

The following comparisons are between the three months ended March 29, 2025 and March 30, 2024 (in thousands):

#### Revenues

	Three Months Ended		Change in \$	Change in %
	March 29, 2025	March 30, 2024		
Cyclo G6	\$ 3,181	\$ 2,953	\$ 228	7.7%
Retina	6,645	6,774	(129)	(1.9%)
Other	2,070	2,034	36	1.8%
Total revenues	<u>\$ 11,896</u>	<u>\$ 11,761</u>	<u>\$ 135</u>	1.1%

Our total revenues increased by \$0.1 million, or 1.1%, from \$11.8 million to \$11.9 million. The increase was driven by an increase in our glaucoma product group and in services and other revenue, partially offset by a decrease in our retina products.

While we believe that the market for our products remains strong, the overall capital expenditure landscape within hospitals, surgical centers and physician offices may continue to be negatively impacted by persistent macroeconomic concerns, including those from ongoing geopolitical uncertainty, tariffs and trade wars.

#### *Gross Profit and Gross Margin*

Gross profit increased \$0.6 million, or 13.4% from \$4.5 million to \$5.1 million. Gross margin increased by 4.6% from 37.9% to 42.5%. The increase in gross margin was the result of lower manufacturing expenses and a more favorable product mix.

Gross margins may fluctuate due to changes in the relative proportion of domestic and international sales, the product mix of sales, introduction of new products, manufacturing variances, total unit volume changes, responses to the evolving macroeconomic and geopolitical uncertainty, including tariffs and trade wars, and other factors.

#### *Research and Development*

Research and development expenses decreased by \$0.7 million, or 43.0% from \$1.6 million to \$0.9 million. The decrease was related to our cost savings measures we implemented, resulting in lower headcount expenses. Spending on investment in new and expanded products was also curtailed.

#### *Sales and Marketing*

Sales and marketing expenses decreased \$1.3 million, or 34.5%, from \$3.7 million to \$2.5 million. The decrease was related to our cost savings measures, including reductions in workforce that resulted in lower headcount expenses, lower consulting expenses, travel expenses, lower tradeshows and public relations expenses, and lower clinical studies expenses.

#### *General and Administrative*

General and administrative expenses decreased by \$0.5 million, or 21.8% from \$2.5 million to \$1.9 million. The decrease is a primarily due to a decrease in consulting costs and deal related legal expenses.

#### *Other Income (Expense), Net*

Other expense, net, was \$1.5 million for the three months ended March 29, 2025, driven primarily by the costs associated with the Lind Note payable settlement. Other expense, net, was \$0.1 million for the three months ended March 30, 2024, consisting primarily of interest and amortization of loan expenses related to the Lind Note transaction.

#### *Income Taxes*

We recorded an income tax provision of \$12 thousand and \$38 thousand for the three months ended March 29, 2025 and March 30, 2024, respectively.

#### *Liquidity, Capital Resources and Management Plans*

Liquidity is our ability to generate sufficient cash flows from operating activities to meet our obligations and commitments. In addition, liquidity includes the ability to obtain appropriate financing or to raise capital.

As of March 29, 2025, we had cash and cash equivalents of \$7.2 million and working capital of \$14.3 million compared to cash and cash equivalents of \$2.4 million and working capital of \$7.0 million as of March 30, 2024.

Net cash used in operating activities was \$1.1 million in the three months ended March 29, 2025 compared to net cash used in operating activities of \$1.6 million in the three months ended March 30, 2024. The increase in net cash provided by operating activities was primarily due to reduction in net loss and reduction in inventory, offset by decreases in collections of accounts receivable and a paydown of liabilities.

For the three months ended March 29, 2025, net cash used in investing activities was \$11 thousand, which consisted of capital expenditures. For the three months ended March 30, 2024, net cash used in investing activities was \$3 thousand, which consisted of capital expenditures.

For the three months ended March 29, 2025, net cash from financing activities was \$6.0 million. We received \$10 million in issuance of convertible preferred shares and convertible debt, offset by \$4.0 million in early prepayment of convertible debt. For the three months ended March 30, 2024, no net cash was used in financing activities.

We have historically funded our operations primarily through sales of our products to customers, sales of our common stock and borrowing arrangements. As of March 29, 2025, our principal sources of liquidity consisted of cash and cash equivalents of \$7.2 million. We have incurred net losses over the last several years, and as of March 29, 2025, have an accumulated deficit of approximately \$89.6 million.

On March 19, 2025, the Company entered into the Novel Securities Agreement and a Note Purchase Agreement and the Novel Note Purchase Agreement with Novel. Pursuant to the Novel Securities Agreement and the Novel Note Purchase Agreement, Novel

has the right to purchase additional convertible promissory notes (the “Growth Notes”) in an aggregate principal amount of \$10,000,000. The Growth Notes are issuable in three installments, with one third of the aggregate principal amount issuable upon each yearly anniversary of the March 19, 2025. Notwithstanding any provision in the Transaction Documents (as defined in the Initial Novel Note) to the contrary, in no circumstance shall the Company be required to deliver to Novel any shares of Series B Preferred Stock or common stock pursuant to the terms of the Transaction Documents to the extent that (i) the aggregate of all such shares issued by the Company would exceed 19.99% of either (a) the total number of shares of common stock outstanding as of March 19, 2025 or (b) the total voting power of the Company’s securities outstanding as of March 19, 2025 that are entitled to vote on a matter being voted on by holders of the common stock, or (ii) such delivery would cause the holder to become, directly or indirectly, a “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) of more than 19.99% of either (a) the total number of shares of common stock outstanding as of such date or (b) the total voting power of the Company’s securities outstanding as of such date that are entitled to vote on a matter being voted on by holders of the common stock, in each case, unless shareholder approval has been obtained

We believe our existing cash and cash equivalents will be sufficient to meet our anticipated cash needs over the next 12 months. Our future capital requirements will depend on many factors, including our growth rate, the timing and extent of our spending to support research and development activities, the timing and cost of establishing additional sales and marketing capabilities, the introduction of new and enhanced products and our costs to implement new manufacturing technologies. Any debt financing obtained by us in the future could also involve restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. Additionally, if we raise additional funds through further issuances of equity, our existing stockholders could suffer significant dilution in their percentage ownership of our company, and any new equity securities we issue could have rights, preferences and privileges senior to those of holders of our common stock.

#### *Off-Balance Sheet Arrangements*

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

### **Item 3. Quantitative and Qualitative Disclosure about Market Risk**

As a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

### **Item 4. Controls and Procedures**

#### *Evaluation of Disclosure Controls and Procedures*

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Principal Executive Officer and our Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and our Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of March 29, 2025. Based on the foregoing, our Principal Executive Officer and our Principal Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

#### *Changes in Internal Control over Financial Reporting*

There have been no changes in our internal control over financial reporting that occurred during the period covered by this Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## **PART II. OTHER INFORMATION**

### **Item 1. Legal Proceedings**

From time to time, we may be involved in legal proceedings arising in the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business, operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

### **Item 1A. Risk Factors**

*An investment in our securities has a high degree of risk. Before you invest you should carefully consider the risks and uncertainties. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial conditions and/or operating results. If any of these risks actually occur, our business, operating results and financial condition could be harmed, and the value of our stock could go down. This means you could lose all or a part of your investment. We have included in Part I, Item 1A in our Annual Report on Form 10-K for the year ended December 28, 2024, which was filed with the SEC on March 27, 2025, a description of certain risks and uncertainties that could affect our business, future performance or financial condition (the "Risk Factors"). There have been no material changes from the disclosure provided in the Form 10-K with respect to the Risk Factors.*

### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

#### **Sales of Unregistered Securities**

None.

### **Item 3. Defaults Upon Senior Securities**

None.

### **Item 4. Mine Safety Disclosures**

Not applicable.

### **Item 5. Other Information**

*Securities Trading Plans of Directors and Executive Officers.*

During the three months ended March 29, 2025, the Company did not adopt or terminate, and no directors or officers, as defined in Rule 16a-1(f), adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," each as defined in Regulation S-K Item 408.

## Item 6. Exhibits

Exhibit No.	Exhibit Title	Incorporated by Reference			Filed Herewith
		Form	Filing No.	Exhibit Filing Date	
3.1	<a href="#">Certificate of Designation, Preferences and Rights of Series B Preferred Stock of Registrant, filed with the Secretary of State of the State of Delaware, March 18, 2025.</a>	8-K	000-27598	3.1 March 20, 2025	
4.1	<a href="#">Investor Rights Agreement, dated March 19, 2025, by and between the Registrant and Novel Inspiration International Co., Ltd.</a>	8-K	000-27598	4.1 March 20, 2025	
10.1	<a href="#">Securities Purchase Agreement, dated March 19, 2025 by and between the Registrant and Novel Inspiration International Co., Ltd.</a>	8-K	000-27598	10.1 March 20, 2025	
10.2	<a href="#">Note Purchase Agreement, dated March 19, 2025, by and between the Registrant and Novel Inspiration International Co., Ltd.</a>	8-K	000-27598	10.2 March 20, 2025	
10.3	<a href="#">Form of Convertible Promissory Note, dated March 19, 2025, by and between the registrant and Novel Inspiration International Co., Ltd.</a>	8-K	000-27598	10.3 March 20, 2025	
10.4	<a href="#">Convertible Promissory Note, dated March 19, 2025, by and between the registrant and Novel Inspiration International Co., Ltd.</a>	8-K	000-27598	10.4 March 20, 2025	
10.5*	<a href="#">Offer Letter between the Registrant and Mr. Dizon.</a>	8-K	000-27598	10.5 March 20, 2025	
10.6*	<a href="#">Change in Control Severance Agreement between the Registrant and Mr. Dizon.</a>	8-K	000-27598	10.6 March 20, 2025	
31.1	<a href="#">Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>				X
31.2	<a href="#">Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>				X
32.1**	<a href="#">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>				X
32.2**	<a href="#">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>				X
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.				X
101.SCH	Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Document.				X
104	Cover Page formatted as Inline XBRL and contained in Exhibit 101				X

\* Indicates a management contract or compensatory plan or arrangement.

\*\* The certification furnished in Exhibit 32.1 and 32.2 hereto is deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

**Trademark Acknowledgments**

Iridex, the Iridex logo, IRIS Medical, MicroPulse, OcuLight, EndoProbe, MicroPulse P3, G-Probe, G-Probe Illuminate, TruFocus LIO Premiere, IQ 577, IQ 532, Cyclo G6, and TxCell are our registered trademarks. All other trademarks or trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

IRIDEX Corporation

Date: May 13, 2025

By: /s/ PATRICK MERCER  
Name: Patrick Mercer  
Title: Chief Executive Officer  
(Principal Executive Officer)

Date: May 13, 2025

By: /s/ ROMEO R. DIZON  
Name: Romeo R. Dizon  
Title: Chief Financial Officer  
(Principal Financial Officer and Principal  
Accounting Officer)

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER  
PURSUANT TO SECTIONS 13(a)-14(a) AND 15(d)-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 AS ADOPTED  
PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Patrick Mercer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of IRIDEX Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 13, 2025

By: /s/ PATRICK MERCER  
Name: Patrick Mercer  
Title: Chief Executive Officer  
(Principal Executive Officer)

---

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER  
PURSUANT TO SECTIONS 13(a)-14(a) AND 15(d)-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 AS ADOPTED  
PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Romeo R. Dizon, certify that:

1. I have reviewed this quarterly report on Form 10-Q of IRIDEX Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 13, 2025

By: /s/ ROMEO R. DIZON  
Name: Romeo R. Dizon  
Title: Chief Financial Officer  
(Principal Financial Officer and Principal  
Accounting Officer)

---

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER  
PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Patrick Mercer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, certify that the Quarterly Report of IRIDEX Corporation on Form 10-Q for the fiscal quarter ended March 29, 2025 (i) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of IRIDEX Corporation.

Date: May 13, 2025

By: /s/ PATRICK MERCER  
Name: Patrick Mercer  
Title: Chief Executive Officer  
(Principal Executive Officer)

---

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER  
PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Romeo R. Dizon, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, certify that the Quarterly Report of IRIDEX Corporation on Form 10-Q for the fiscal quarter ended March 29, 2025 (i) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of IRIDEX Corporation.

Date: May 13, 2025

By: /s/ ROMEO R. DIZON  
Name: Romeo R. Dizon  
Title: Chief Financial Officer  
(Principal Financial Officer and Principal Accounting  
Officer)

---

